CA2940237C - Antimitotic amides for the treatment of cancer and proliferative disorders - Google Patents
Antimitotic amides for the treatment of cancer and proliferative disorders Download PDFInfo
- Publication number
- CA2940237C CA2940237C CA2940237A CA2940237A CA2940237C CA 2940237 C CA2940237 C CA 2940237C CA 2940237 A CA2940237 A CA 2940237A CA 2940237 A CA2940237 A CA 2940237A CA 2940237 C CA2940237 C CA 2940237C
- Authority
- CA
- Canada
- Prior art keywords
- unsubstituted
- substituted
- compound
- salt
- nrarb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461942956P | 2014-02-21 | 2014-02-21 | |
| US61/942,956 | 2014-02-21 | ||
| PCT/US2015/016928 WO2015127284A2 (en) | 2014-02-21 | 2015-02-20 | Antimitotic amides for the treatment of cancer and proliferative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2940237A1 CA2940237A1 (en) | 2015-08-27 |
| CA2940237C true CA2940237C (en) | 2023-03-07 |
Family
ID=52684675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2940237A Active CA2940237C (en) | 2014-02-21 | 2015-02-20 | Antimitotic amides for the treatment of cancer and proliferative disorders |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US10016398B2 (https=) |
| EP (1) | EP3107909B1 (https=) |
| JP (1) | JP6506313B2 (https=) |
| KR (1) | KR102420508B1 (https=) |
| CN (2) | CN114634483B (https=) |
| AU (1) | AU2015218775C1 (https=) |
| BR (1) | BR112016019161B1 (https=) |
| CA (1) | CA2940237C (https=) |
| ES (1) | ES2893374T3 (https=) |
| IL (1) | IL247293B (https=) |
| MX (1) | MX390530B (https=) |
| RU (1) | RU2713179C2 (https=) |
| SG (2) | SG11201606869TA (https=) |
| WO (1) | WO2015127284A2 (https=) |
| ZA (1) | ZA201606471B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6420622B1 (en) | 1997-08-01 | 2002-07-16 | 3M Innovative Properties Company | Medical article having fluid control film |
| SG11201606869TA (en) * | 2014-02-21 | 2016-09-29 | Frost Biolog Inc | Antimitotic amides for the treatment of cancer and proliferative disorders |
| CN106727583A (zh) * | 2016-12-12 | 2017-05-31 | 范旭升 | 一种治疗舒张性心衰的药物组合物 |
| US11377436B2 (en) * | 2017-07-12 | 2022-07-05 | The Brigham And Women's Hospital, Inc. | EAAT2 enhancing molecules |
| WO2019168874A1 (en) | 2018-02-27 | 2019-09-06 | The Research Foundation For The State University Of New York | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
| KR20250173438A (ko) * | 2024-05-30 | 2025-12-10 | 삼진제약주식회사 | Nr2f6 억제제 및 이의 용도 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001930D0 (en) | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| BR0111280A (pt) * | 2000-06-05 | 2003-06-10 | Dong A Pharm Co Ltd | Novos derivados de oxazolidinona e um processo para a preparação dos mesmos |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| GB0209715D0 (en) * | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| CN1976703A (zh) * | 2004-06-30 | 2007-06-06 | 诺瓦提斯公司 | 通过使用外排泵抑制剂增加肽脱甲酰基酶抑制剂敏感性的方法 |
| US20090156646A1 (en) * | 2005-08-11 | 2009-06-18 | Takeda Pharmaceutical Company Limited | Pyridylphenol compound and use thereof |
| US20070254926A1 (en) * | 2006-01-31 | 2007-11-01 | Jun Jiang | Pyridylphenyl compounds for inflammation and immune-related uses |
| EP2086966B1 (en) | 2006-11-17 | 2011-09-14 | GlaxoSmithKline LLC | 2-carboxy thiophene derivatives as anti viral agents |
| BRPI0810641A2 (pt) * | 2007-04-12 | 2019-09-24 | Hoffmann La Roche | "compostos farmacêuticos". |
| WO2010039236A1 (en) * | 2008-10-01 | 2010-04-08 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| WO2010100475A1 (en) * | 2009-03-02 | 2010-09-10 | Astrazeneca Ab | Hydroxamic acid derivatives as gram-negative antibacterial agents |
| HUE024568T2 (hu) * | 2009-09-11 | 2016-02-29 | Amgen Inc | N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamin antimitotikus szerre rezisztens rák kezelésében történõ alkalmazásra |
| DK2563776T3 (en) * | 2010-04-27 | 2016-09-19 | Calcimedica Inc | Relations that modulate intracellular calcium |
| WO2011142151A1 (ja) * | 2010-05-14 | 2011-11-17 | シャープ株式会社 | 携帯型情報端末およびその制御方法 |
| TWI541243B (zh) * | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| US8859546B2 (en) * | 2011-01-21 | 2014-10-14 | Abbvie Inc. | Picolinamide inhibitors of kinases |
| BR112013020270A2 (pt) * | 2011-02-10 | 2016-07-12 | Syngenta Participations Ag | derivados de pirazol microbicidas |
| EP2704701B1 (en) * | 2011-05-03 | 2018-01-03 | PRCL Research Inc. | Compounds for inflammation and immune-related uses |
| US20140242099A1 (en) | 2011-10-28 | 2014-08-28 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| SG11201606869TA (en) * | 2014-02-21 | 2016-09-29 | Frost Biolog Inc | Antimitotic amides for the treatment of cancer and proliferative disorders |
-
2015
- 2015-02-20 SG SG11201606869TA patent/SG11201606869TA/en unknown
- 2015-02-20 KR KR1020167026016A patent/KR102420508B1/ko active Active
- 2015-02-20 CN CN202210190090.XA patent/CN114634483B/zh active Active
- 2015-02-20 BR BR112016019161-7A patent/BR112016019161B1/pt active IP Right Grant
- 2015-02-20 CA CA2940237A patent/CA2940237C/en active Active
- 2015-02-20 RU RU2016135555A patent/RU2713179C2/ru active
- 2015-02-20 EP EP15710328.4A patent/EP3107909B1/en active Active
- 2015-02-20 US US15/120,470 patent/US10016398B2/en active Active
- 2015-02-20 SG SG10202000590SA patent/SG10202000590SA/en unknown
- 2015-02-20 MX MX2016010877A patent/MX390530B/es unknown
- 2015-02-20 WO PCT/US2015/016928 patent/WO2015127284A2/en not_active Ceased
- 2015-02-20 JP JP2016570919A patent/JP6506313B2/ja active Active
- 2015-02-20 ES ES15710328T patent/ES2893374T3/es active Active
- 2015-02-20 CN CN201580009889.2A patent/CN106068263A/zh active Pending
- 2015-02-20 AU AU2015218775A patent/AU2015218775C1/en active Active
-
2016
- 2016-08-16 IL IL247293A patent/IL247293B/en active IP Right Grant
- 2016-09-20 ZA ZA2016/06471A patent/ZA201606471B/en unknown
-
2018
- 2018-06-29 US US16/024,407 patent/US10772872B2/en active Active
-
2020
- 2020-09-03 US US17/011,589 patent/US11129813B2/en active Active
-
2021
- 2021-09-13 US US17/473,364 patent/US12383533B2/en active Active
-
2025
- 2025-08-12 US US19/297,804 patent/US20260034101A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12383533B2 (en) | Antimitotic amides for the treatment of cancer and proliferative disorders | |
| JP5753927B2 (ja) | 有機化合物 | |
| CA3095019C (en) | Substituted pyridine derivatives and compositions thereof useful as inhibitors of histone demethylases | |
| CZ291791B6 (cs) | Amidy pyridylalkenové a pyridylalkinové kyseliny jako cytostatika a imunosupresiva | |
| BRPI0720635A2 (pt) | Compostos orgânicos e seus usos | |
| JP5094721B2 (ja) | Ｎ−フェニル−２−ピリミジン−アミン誘導体及びそれの調製のための工程 | |
| JPWO2012036278A1 (ja) | グリシントランスポーター阻害物質 | |
| EA036542B1 (ru) | Галоген-замещенные пиперидины в качестве модуляторов орексинового рецептора | |
| JP6569678B2 (ja) | ２−アミノチアゾール誘導体またはその塩 | |
| CN118434743A (zh) | 三环杂环类 | |
| KR101297652B1 (ko) | 항암활성을 지닌 카르보아졸계 화합물 | |
| HK1232858B (en) | Antimitotic amides for the treatment of cancer and proliferative disorders | |
| MX2014001052A (es) | Compuesto novedoso que tiene actividad inhibidora de angiogénesis, metodo para preparar del mismo, y composicion farmaceutica que comprende el mismo. | |
| WO2012115066A1 (ja) | グリシントランスポーター阻害物質 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200221 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - SMALL Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250214 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250214 |